Prana looks at Huntington’s
Tuesday, 02 December, 2008
Melbourne company Prana Biotechnology is investigating the potential of its lead compound, PBT2, in Huntington’s disease.
PBT2, a metal-protein-attenuating compound (MPAC), is in Phase IIb clinical trials for Alzheimer’s disease.
The compound reduces the toxic metal-protein interaction seen in both neurological diseases and has a neuroprotective effect.
Chairman of Prana’s R&D advisory board, Professor Jeffery Cummings, told the company’s AGM that a report commissioned from an independent clinical research group recommended that Prana proceed to clinical trials.
Prana is in confidential talks with several pharma companies with a view to licensing PBT2, the company said.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
